1.74
Precedente Chiudi:
$1.71
Aprire:
$1.69
Volume 24 ore:
71,956
Relative Volume:
0.19
Capitalizzazione di mercato:
$30.60M
Reddito:
Utile/perdita netta:
$-22.70M
Rapporto P/E:
-0.50
EPS:
-3.4798
Flusso di cassa netto:
$-16.66M
1 W Prestazione:
-10.77%
1M Prestazione:
+17.57%
6M Prestazione:
-60.27%
1 anno Prestazione:
-82.79%
Cel-Sci Corp. Stock (CVM) Company Profile
Nome
Cel-Sci Corp.
Settore
Industria
Telefono
703-506-9460
Indirizzo
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
CVM
Cel-Sci Corp.
|
1.74 | 30.60M | 0 | -22.70M | -16.66M | -3.4798 |
|
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-02 | Iniziato | Dawson James | Buy |
Cel-Sci Corp. Borsa (CVM) Ultime notizie
Cel-Sci Corporation (CVM) Jumps 11.98% to $2.71 as Buyers Push Toward ResistanceETF AUM Growth - https://www.siam.in/
Form 4 CEL-SCI Corp For: 1 October By Investing.com - Investing.com Australia
CEL SCI Corp CSO Eyal Talor Purchases 1,165 Shares of Common Stock - Kalkine Media
A 1,165-share award brings Eyal Talor’s direct CEL SCI CORP (CVM) holdings to 10,483 shares. - stocktitan.net
A 2,082-share award brings CEL SCI CORP (CVM) CFO Patricia B. Prichep's direct holding to 19,571 shares. - stocktitan.net
A 2,621-share grant leaves CEL SCI CORP (CVM) CEO holding 318,763 shares directly. - stocktitan.net
Cel-Sci Corporation (CVM) Stock Analysis: Unpacking The 738% Potential Upside - DirectorsTalk Interviews
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology - Investing News Network
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology - Yahoo Finance
CEL-SCI Corp (CVM) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com Nigeria
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com South Africa
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com UK
CEL SCI (CVM) CEO adds 100K restricted shares to his stake - Stock Titan
Cel-Sci (CVM) Outlook: Ends Up by 3.14% at $1.64 for the Current Session; Key Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseHagopian Line - vinanet.vn
CEL-SCI Company Profile & Introduction - Moomoo
CEL-SCI closes $2.5M offering to fund Multikine - scanx.trade
CEL-SCI Q3 Results: Per-share loss narrows 65% YoY to $(0.47) - scanx.trade
Cel-Sci shareholders elect directors and approve compensation plans at annual meeting - Investing.com
CEL SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI (NYSE: CVM) awards CEO 300,000 options over 3 years - Stock Titan
CEL-SCI (NYSE: CVM) awards Cipriano 80K options vesting over 3 years - Stock Titan
CEL-SCI (CVM) awards CSO Talor Eyal 250,000 stock options - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Nigeria
CEL-SCI (NYSEAMERICAN: CVM) CFO lands new 2036 stock option grant - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Canada
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com India
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com UK
CEL-SCI (CVM) Advances Multikine Trial Amid Low Valuation and Gu - GuruFocus
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Yahoo Finance
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Investing News Network
Cel-Sci: Fiscal Q3 Earnings Snapshot - marketscreener.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - AOL.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - cbs19news.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - KTVB
CEL-SCI (CVM) faces going concern risk amid $16.6M loss and $6.5M cash - Stock Titan
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Stock News Today - tradingkey.com
CEL-SCI publishes study on Multikine cancer treatment biomarkers - Investing.com
CEL-SCI (CVM) Advances Oral Cancer Immunotherapy Amid Challengin - GuruFocus
Before surgery, Multikine cut disease-progression risk 49% in study - Stock Titan
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Yahoo Finance
CEL-SCI Trial Reports 73% Five-Year Survival in Low PD-L1 Oral Cancer - Stock Titan
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Yahoo Finance
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Investing News Network
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Business Wire
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
Cel-Sci Corp. Azioni (CVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cel-Sci Corp. Azioni (CVM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KERSTEN GEERT R | Chief Executive Officer |
May 14 '26 |
Buy |
1.20 |
300,000 |
360,000 |
311,547 |
| KERSTEN GEERT R | Chief Executive Officer |
May 13 '26 |
Buy |
1.19 |
100,000 |
119,000 |
222,497 |
| KERSTEN GEERT R | Chief Executive Officer |
Jan 22 '26 |
Buy |
5.26 |
38,023 |
200,001 |
120,815 |
| KERSTEN GEERT R | Chief Executive Officer |
Dec 04 '25 |
Buy |
5.96 |
8,389 |
49,998 |
81,794 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):